Literature DB >> 15972964

Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors.

Patricia Parsons-Wingerter1, Ian M Kasman, Scott Norberg, Anette Magnussen, Sara Zanivan, Alberto Rissone, Peter Baluk, Cecile J Favre, Ursula Jeffry, Richard Murray, Donald M McDonald.   

Abstract

Integrin alpha5beta1 is among the proteins overexpressed on tumor vessels and is a potential target for diagnostics and therapeutics. Here, we mapped the distribution of alpha5beta1 integrin in three murine tumor models and identified sites of expression that are rapidly accessible to intravascular antibodies. When examined by conventional immunohistochemistry, alpha5beta1 integrin expression was strong on most blood vessels in RIP-Tag2 transgenic mouse tumors, adenomatous polyposis coli (apc) mouse adenomas, and implanted MCa-IV mammary carcinomas. Expression increased during malignant progression in RIP-Tag2 mice. However, immunoreactivity was also strong in normal pancreatic ducts, intestinal smooth muscle, and several other sites. To determine which sites of expression were rapidly accessible from the bloodstream, we intravenously injected anti-alpha5beta1 integrin antibody and 10 minutes to 24 hours later examined the amount and distribution of labeling. The injected antibody strongly labeled tumor vessels at all time points but did not label most normal blood vessels or gain access to pancreatic ducts or intestinal smooth muscle. Intense vascular labeling by anti-alpha5beta1 integrin antibody co-localized with the uniform CD31 immunoreactivity of tumor vessels and contrasted sharply with the patchy accumulation of nonspecific IgG at sites of leakage. This strategy of injecting antibodies revealed the uniform overexpression and rapid accessibility of alpha5beta1 integrin on tumor vessels and may prove useful in assessing other potential therapeutic targets in cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972964      PMCID: PMC1603436          DOI: 10.1016/s0002-9440(10)62965-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Genes expressed in human tumor endothelium.

Authors:  B St Croix; C Rago; V Velculescu; G Traverso; K E Romans; E Montgomery; A Lal; G J Riggins; C Lengauer; B Vogelstein; K W Kinzler
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

Review 2.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

3.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.

Authors:  C J Bruns; W Liu; D W Davis; R M Shaheen; D J McConkey; M R Wilson; C D Bucana; D J Hicklin; L M Ellis
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

4.  Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies.

Authors:  D Taverna; R O Hynes
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

5.  Fibronectin accumulation in glomerulosclerotic lesions: self-assembly sites and the heparin II binding domain.

Authors:  Anita I van Vliet; Isolde E van Alderwegen; Hans J Baelde; Emile de Heer; Jan A Bruijn
Journal:  Kidney Int       Date:  2002-02       Impact factor: 10.612

6.  Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis.

Authors:  Matthew R Ritter; Michael I Dorrell; Joseph Edmonds; Sheila Fallon Friedlander; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.

Authors:  R M Shaheen; D W Davis; W Liu; B K Zebrowski; M R Wilson; C D Bucana; D J McConkey; G McMahon; L M Ellis
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

8.  In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.

Authors:  F Mitjans; T Meyer; C Fittschen; S Goodman; A Jonczyk; J F Marshall; G Reyes; J Piulats
Journal:  Int J Cancer       Date:  2000-09-01       Impact factor: 7.396

9.  Fibrinogen binds to integrin alpha(5)beta(1) via the carboxyl-terminal RGD site of the Aalpha-chain.

Authors:  K Suehiro; J Mizuguchi; K Nishiyama; S Iwanaga; D H Farrell; S Ohtaki
Journal:  J Biochem       Date:  2000-10       Impact factor: 3.387

10.  Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity.

Authors:  Flavio Curnis; Anna Gasparri; Angelina Sacchi; Renato Longhi; Angelo Corti
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

View more
  23 in total

1.  A decorin-deficient matrix affects skin chondroitin/dermatan sulfate levels and keratinocyte function.

Authors:  Katerina Nikolovska; Jana K Renke; Oliver Jungmann; Kay Grobe; Renato V Iozzo; Alina D Zamfir; Daniela G Seidler
Journal:  Matrix Biol       Date:  2014-01-18       Impact factor: 11.583

2.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

Authors:  Kenjiro Sawada; Anirban K Mitra; A Reza Radjabi; Vinay Bhaskar; Emily O Kistner; Maria Tretiakova; Sujatha Jagadeeswaran; Anthony Montag; Amy Becker; Hilary A Kenny; Marcus E Peter; Vanitha Ramakrishnan; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

3.  Integrin alpha5beta1 mediates attachment, migration, and proliferation in human retinal pigment epithelium: relevance for proliferative retinal disease.

Authors:  Rong Li; Arvydas Maminishkis; Grit Zahn; Doerte Vossmeyer; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

4.  alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation.

Authors:  Tatsuma Okazaki; Amy Ni; Oluwasheyi A Ayeni; Peter Baluk; Li-Chin Yao; Doerte Vossmeyer; Gunther Zischinsky; Grit Zahn; Jochen Knolle; Claudia Christner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

5.  Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1.

Authors:  Ming-Yi Lee; Jian-Pei Huang; Yi-Yung Chen; John D Aplin; Yi-Hsin Wu; Chia-Yu Chen; Pei-Chun Chen; Chie-Pein Chen
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

6.  Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.

Authors:  Alejandro D Ricart; Anthony W Tolcher; Glenn Liu; Kyle Holen; Garry Schwartz; Mark Albertini; Geoffrey Weiss; Salim Yazji; Chee Ng; George Wilding
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

7.  Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.

Authors:  Hooi Tin Ong; Theodore R Trejo; Linh D Pham; Ann L Oberg; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

8.  Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.

Authors:  Anne H Schmieder; Shelton D Caruthers; Huiying Zhang; Todd A Williams; J David Robertson; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2008-08-12       Impact factor: 5.191

9.  An antimetastatic role for decorin in breast cancer.

Authors:  Silvia Goldoni; Daniela G Seidler; Jack Heath; Matteo Fassan; Raffaele Baffa; Mathew L Thakur; Rick T Owens; David J McQuillan; Renato V Iozzo
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

10.  Myosin IIC: a third molecular motor driving neuronal dynamics.

Authors:  Steven R Wylie; Peter D Chantler
Journal:  Mol Biol Cell       Date:  2008-07-09       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.